In 2020, bladder cancer caused approximately 67,000 deaths in Europe.
We are striving to reduce this threat, and are dedicated to helping patients and their loved ones find hope and relief. To do this, we are developing targeted therapies and deepening our understanding of this complex disease.
Our understanding of bladder cancer
People living with the disease often face poor outcomes, a 5% survival rate over five years for metastatic settings. At Janssen we are embracing this challenge.
There is strong scientific evidence to show that the earlier the diagnosis of bladder cancer, the better the prognosis is for patients.
Bladder cancer in numbers
Bladder cancer incidence is approximately 5x more in men than in women.
Since the mid- to late- 1990s, bladder cancer incidence rates have been stabilising or decreasing in men from Western and Northern Europe (other than in the Baltic countries), but increasing in Southern, Central, and Eastern Europe
Mortality rates in European men were by far the highest recorded worldwide, notably in Eastern Europe and the Baltic countries
The power of targeted transformation
We are focusing on better understanding the drivers of urothelial cancer, the most common type of bladder cancer and are exploring targeted therapies - alone and in combination - to transform outcomes. At Janssen Oncology, average isn’t good enough. We’re driven only to deliver the best outcomes to patients, partners, and the oncology community.
We see enormous potential in the use of companion diagnostics, to ensure patients have access to the latest and most appropriate therapeutic opportunities.
Recent research efforts in the field of precision oncology have provided key insights that have transformed the treatment paradigm, and will undoubtedly continue to expand our therapeutic options in the years to come.
Evidence suggests that the FGFR pathway may provide another option for treating bladder cancer. Current phase 3 trials are ongoing to investigate the use of FGFR inhibitors to treat FGFR3-altered metastatic urothelial carcinoma.
We collaborate to innovate
We fiercely believe cancer is a challenge we can collectively overcome, and our ultimate aim is to make cancer a manageable, even curable, condition. We know that change can only come through collaboration. We invest our time, expertise, and resources and partner with experts to unlock the potential around us, all in pursuit of better outcomes for patients and their families.
We’re very excited about the opportunity to advance the science of genitourinary cancers and improve the care of patients diagnosed with bladder cancer through our acquisition of TARIS Biomedical LLC in 2019. The TARIS technology is a first-in-class clinical platform which delivers therapeutics locally to patients diagnosed with bladder cancer. The silicone-based delivery device allows for the continuous release of medication directly to tumours located in the bladder.
We believe that the TARIS bladder-specific drug-delivery platform has the potential to be transformative in delivering active treatments locally with the ability to combine with systemic therapies to develop curative regimens for early stage non-muscle and muscle invasive bladder cancer patients.Find out more
Partner with us
Janssen Oncology is committed to ensuring success in our collaborations. Our Johnson & Johnson Innovation and Janssen Business Development teams bring scientific and commercial expertise, while our flexible structure enables us to work effectively with a variety of partners to create the best business model for each collaboration.
We look for collaborations in which each partner brings unique strengths and experiences, so that together we can achieve more than either could alone.
Learn more about our partnerships